Digest Réseau Comment ça marche
Réseau
/
Sociétés
As
Non vérifié

AstraZeneca

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

126 communiqués de presse

Voir tous les communiqués de presse
25/09/2026
Industrie
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
14/09/2026
Science
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Industrie
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
14/09/2026
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
08/09/2026
Industrie
Science
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
08/09/2026
Événements
Industrie
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Médecine - Divers
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
04/09/2026
Industrie
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Industrie pharmaceutique
Vitrines/Shopping
Santé
Oncologie
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
01/09/2026
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
27/08/2026
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
17/08/2026
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Source
AstraZeneca
Émetteur
Business Wire
1.00
0
17/08/2026
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Source
AstraZeneca
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0